New Immunotherapy Institute will promote research, educational initiatives and faculty development. Credit: Beth Israel Deaconess Medical Center.

The Cancer Center at the Beth Israel Deaconess Medical Center (BIDMC) in the US has opened a clinical and research institute focused on cancer immunotherapy.

The immunotherapy institute will encourage research, educational initiatives and faculty development to further advance immunotherapies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Immunotherapy uses the body’s natural defence systems to detect and selectively target cancer cells while minimising toxicity to vital tissues. It is currently used to treat different types of cancer, including blood, colon, kidney, skin and breast cancer.

The new facility will drive better insights into cancer immunotherapy for the development of new therapies.

Researchers at the institute are already working on combining clinical and translational research under a personalised cancer vaccine programme.

“It’s incredibly powerful to bring together a community of scientists, clinicians, translational researchers, patients and families with the shared goal of improving patient outcomes.”

In previous clinical trials with certain blood cancer patients, the team observed that vaccines developed at BIDMC trigger anti-tumour immune responses, disease regression and protection from relapse.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on these findings, BIDMC is expanding access to this technology to patients across the country through a new clinical trial involving 17 US cancer centres.

The institute will be supported by BIDMC’s Randi and Brian Schwartz Family Cancer Immunotherapy and Cell Manipulation Facility to advance its vaccine research and develop innovative technologies.

BIDMC Cell Therapy and Bone Marrow Transplant Program, hematologic malignancies section chief David Avigan said: “The idea of using the immune system as a way of developing better and curative therapies is an incredible motivator for all of us.

“It’s incredibly powerful to bring together a community of scientists, clinicians, translational researchers, patients and families with the shared goal of improving patient outcomes.”